|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||74.32 / 75.00|
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
The market is doing well early into the new trading week. The Dow is up some 250 points to new all-time highs as investors applaud the new NAFTA agreement. I think this deal is timely given the ISM manufacturing index in September fell slightly on c...
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
I'll answer some of frequent questions I am hearing from readers in recent weeks.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.
Here's a closer look at four of venture capital funds' favorite publicly traded names in 2017.
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro is not giving up its big takeover speculation rise yesterday and is up another 3%...
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...
M&A activity should perk up substantially in the small and mid-cap space this year.
U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.